Laxmi Organic Industries Limited (LXCHEM.BO)
INR 252.6
(0.0%)
INR 252.6
(0.0%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 5.53 Billion | 1.99 Billion | 649.9 Million | 1.06 Billion | 1.95 Billion | 1.87 Billion |
| Net Income | 1.2 Billion | 1.72 Billion | 3.18 Billion | 1.58 Billion | 551.38 Million | 975.89 Million |
| Depreciation & Amortization | 1.06 Billion | 724.12 Million | 481.02 Million | 465.23 Million | 488.89 Million | 440.59 Million |
| Deferred income taxes | - | -459.84 Million | -481.24 Million | -258.47 Million | - | - |
| Stock-based compensation | 168.43 Million | 114.17 Million | 231.32 Million | 46.36 Million | - | - |
| Change in working capital | 3.08 Billion | -132.93 Million | -2.73 Billion | -888.3 Million | 1 Billion | 566.68 Million |
| Other non-cash items | -593.37 Million | 15.93 Million | -38.31 Million | 113.05 Million | -92.53 Million | -106.63 Million |
| Investing Cash Flow | -5.02 Billion | -3.84 Billion | 546.06 Million | -6.41 Billion | -559.13 Million | -1.22 Billion |
| Investments in PPE | -2.47 Billion | -4.75 Billion | -2.89 Billion | -1.15 Billion | -772.34 Million | -974.88 Million |
| Acquisitions | 1.87 Million | -15.12 Million | -400.1 Million | -12.5 Million | 1.06 Million | 2.9 Million |
| Investment purchases | -13.44 Billion | -10.04 Billion | -10.35 Billion | -1.9 Billion | -918.02 Million | -337.76 Million |
| Sales/Maturities of investments | 10.89 Billion | 9.89 Billion | 10.34 Billion | 1.68 Billion | 179.68 Million | 71.82 Million |
| Other Investing Activities | -1.56 Billion | 1.08 Billion | 3.85 Billion | -5.03 Billion | 950.49 Million | 12.44 Million |
| Financing Cash Flow | -207.29 Million | 2.32 Billion | -1.23 Billion | 5.27 Billion | -1.23 Billion | -626.96 Million |
| Debt repayment | -2.61 Billion | -99.76 Million | -1.36 Billion | -944.46 Million | -670.76 Million | -264.64 Million |
| Dividends payments | -132.78 Million | -185.57 Million | -131.83 Million | -78.78 Million | -21.12 Million | -15.01 Million |
| Common Stock Repurchased | - | 2.51 Billion | - | 1.29 Billion | -820.13 Million | - |
| Common Stock Issuance | 2.57 Billion | 93.75 Million | - | 5 Billion | 361.83 Million | - |
| Other Financing Activities | -2.43 Million | 2.46 Million | 258.08 Million | 690 Thousand | -84.97 Million | -347.31 Million |
| Accounts receivables | -171.42 Million | 919.56 Million | -2.01 Billion | -752.53 Million | -357.11 Million | -6.48 Million |
| Accounts payables | 2.96 Billion | -2.43 Billion | 1.34 Billion | 637.43 Million | 1.02 Billion | 1.01 Billion |
| Inventory | 108.78 Million | 795.95 Million | -1.23 Billion | -514.12 Million | 188.58 Million | -249.16 Million |
| Other working capital | 186.51 Million | 589.73 Million | -819.59 Million | -259.08 Million | 154.96 Million | -192.07 Million |
| Cash at beginning of period | 818.41 Million | 336.12 Million | 166.16 Million | 241.1 Million | 76.45 Million | 52.36 Million |
| Cash at end of period | 3.17 Billion | 810.14 Million | 336.12 Million | 166.16 Million | 241.1 Million | 76.45 Million |
| Capital Expenditure | -2.47 Billion | -4.75 Billion | -2.89 Billion | -1.15 Billion | -772.34 Million | -974.88 Million |
| Effect of forex changes on cash | - | - | 212.9 Million | - | 80 Thousand | - |
| Net cash flow / Change in cash | 2.35 Billion | 474.02 Million | 169.96 Million | -74.94 Million | 164.65 Million | 24.09 Million |
| Free Cash Flow | 3.05 Billion | -2.76 Billion | -2.24 Billion | -89.44 Million | 1.18 Billion | 901.65 Million |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 343.51 Million | 1.2 Billion | 443.04 Million | 271.89 Million | 107.13 Million | 383.29 Million |
| Depreciation & Amortization | - | 1.06 Billion | - | 275.3 Million | 275.49 Million | 209.6 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | 168.43 Million | 168.43 Million | - | - | - |
| Change in working capital | - | 3.08 Billion | - | - | - | - |
| Other non-cash items | -343.51 Million | -593.37 Million | -611.47 Million | -271.89 Million | -107.13 Million | -383.29 Million |
| Investing Cash Flow | - | -5.02 Billion | - | - | - | - |
| Investments in PPE | - | -2.47 Billion | - | - | - | - |
| Acquisitions | - | 1.87 Million | - | - | - | - |
| Investment purchases | - | -13.44 Billion | - | - | - | - |
| Sales/Maturities of investments | - | 10.89 Billion | - | - | - | - |
| Other Investing Activities | - | -1.56 Billion | - | - | - | - |
| Financing Cash Flow | - | -207.29 Million | - | - | - | - |
| Debt repayment | - | -2.61 Billion | - | - | - | - |
| Dividends payments | - | -132.78 Million | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 2.57 Billion | - | - | - | - |
| Other Financing Activities | - | -2.43 Million | - | - | - | - |
| Accounts receivables | - | -171.42 Million | - | - | - | - |
| Accounts payables | - | 2.96 Billion | - | - | - | - |
| Inventory | - | 108.78 Million | - | - | - | - |
| Other working capital | - | 186.51 Million | - | - | - | - |
| Cash at beginning of period | - | 818.41 Million | - | 892.14 Million | 785.01 Million | 818.41 Million |
| Cash at end of period | - | 3.17 Billion | - | 271.89 Million | 892.14 Million | 383.29 Million |
| Capital Expenditure | - | -2.47 Billion | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | 2.35 Billion | - | -620.25 Million | 107.13 Million | -435.12 Million |
| Free Cash Flow | - | 3.05 Billion | - | 271.89 Million | 107.13 Million | 383.29 Million |
RXMD
MOREPENLAB
GBLX
MAXHEALTH
PHVS
TI